Investors Purchase High Volume of Poseida Therapeutics Put Options (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the target of some unusual options trading on Tuesday. Traders bought 5,174 put options on the company. This is an increase of approximately 3,372% compared to the average volume of 149 put options.

Insider Activity at Poseida Therapeutics

In related news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares in the company, valued at approximately $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Poseida Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the period. Vanguard Group Inc. boosted its position in shares of Poseida Therapeutics by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares during the period. Advantage Alpha Capital Partners LP acquired a new stake in shares of Poseida Therapeutics in the third quarter valued at about $285,000. Public Employees Retirement System of Ohio raised its holdings in shares of Poseida Therapeutics by 177.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after buying an additional 40,245 shares during the period. Finally, Lazard Asset Management LLC lifted its position in Poseida Therapeutics by 280.3% during the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after acquiring an additional 21,138 shares in the last quarter. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Analyst Upgrades and Downgrades

PSTX has been the subject of a number of research analyst reports. BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday. Cantor Fitzgerald lowered shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Finally, William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Poseida Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Stock Down 0.5 %

PSTX opened at $9.33 on Thursday. Poseida Therapeutics has a 1 year low of $1.87 and a 1 year high of $9.42. The firm has a 50 day moving average price of $3.02 and a 200 day moving average price of $3.01. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The company has a market cap of $909.35 million, a PE ratio of -14.81 and a beta of 0.54.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.